{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T04:44:13Z","timestamp":1787978653915,"version":"build-2784847793"},"reference-count":326,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T00:00:00Z","timestamp":1725062400000},"content-version":"am","delay-in-days":304,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA266057"],"award-info":[{"award-number":["R01CA266057"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21AI159323"],"award-info":[{"award-number":["R21AI159323"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RP220232"],"award-info":[{"award-number":["RP220232"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ejmech.2023.115772","type":"journal-article","created":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T12:12:39Z","timestamp":1693224759000},"page":"115772","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":77,"special_numbering":"C","title":["Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review"],"prefix":"10.1016","volume":"260","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0189-4371","authenticated-orcid":false,"given":"Xin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongcheng","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejmech.2023.115772_bib1","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1016\/S1473-3099(20)30129-8","article-title":"Can we contain the COVID-19 outbreak with the same measures as for SARS?","volume":"20","author":"Wilder-Smith","year":"2020","journal-title":"Lancet Infect. Dis."},{"issue":"18","key":"10.1016\/j.ejmech.2023.115772_bib2","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1056\/NEJMp2003762","article-title":"Responding to Covid-19\u2014a once-in-a-century pandemic?","volume":"382","author":"Gates","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.ejmech.2023.115772_bib3","doi-asserted-by":"crossref","DOI":"10.3201\/eid2607.200282","article-title":"High Contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2","volume":"26","author":"Sanche","year":"2020","journal-title":"Emerg. Infect. Dis."},{"issue":"8","key":"10.1016\/j.ejmech.2023.115772_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2020.100618","article-title":"COVID-19 and multiorgan response","volume":"45","author":"Zaim","year":"2020","journal-title":"Curr. Probl. Cardiol."},{"key":"10.1016\/j.ejmech.2023.115772_bib5","first-page":"1","article-title":"Therapeutic strategies for COVID-19: progress and lessons learned","author":"Li","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.ejmech.2023.115772_bib6","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/cbic.202000047","article-title":"Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019\u2010nCoV","volume":"21","author":"Morse","year":"2020","journal-title":"Chembiochem"},{"issue":"3","key":"10.1016\/j.ejmech.2023.115772_bib7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","article-title":"Coronavirus biology and replication: implications for SARS-CoV-2","volume":"19","author":"V\u2019kovski","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115772_bib8","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1074\/jbc.M310875200","article-title":"Biosynthesis, purification, and substrate specificity of severe acute respiratory syndrome coronavirus 3C-like proteinase","volume":"279","author":"Fan","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115772_bib9","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.drudis.2020.01.015","article-title":"Recent discovery and development of inhibitors targeting coronaviruses","volume":"25","author":"Pillaiyar","year":"2020","journal-title":"Drug Discov. Today"},{"issue":"7","key":"10.1016\/j.ejmech.2023.115772_bib10","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1128\/JVI.06540-11","volume":"86","author":"Woo","year":"2012","journal-title":"J. Virol."},{"issue":"9997","key":"10.1016\/j.ejmech.2023.115772_bib11","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(15)60454-8","article-title":"Middle East respiratory syndrome","volume":"386","author":"Zumla","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ejmech.2023.115772_bib12","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","article-title":"Origin and evolution of pathogenic coronaviruses","volume":"17","author":"Cui","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejmech.2023.115772_bib13","series-title":"Open Forum Infectious Diseases","article-title":"Human coronavirus-HKU1 infection among adults in Cleveland, Ohio","author":"Kanwar","year":"2017"},{"issue":"4","key":"10.1016\/j.ejmech.2023.115772_bib14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1750-2659.2008.00049.x","article-title":"Human coronavirus NL63 infections in infants hospitalised with acute respiratory tract infections in South Africa","volume":"2","author":"Smuts","year":"2008","journal-title":"Influenza and other respiratory viruses"},{"issue":"7","key":"10.1016\/j.ejmech.2023.115772_bib15","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1086\/377612","article-title":"Coronavirus 229E-related pneumonia in immunocompromised patients","volume":"37","author":"Pene","year":"2003","journal-title":"Clin. Infect. Dis."},{"issue":"10","key":"10.1016\/j.ejmech.2023.115772_bib16","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/infdis\/jit393","article-title":"Clinical impact of human coronaviruses 229E and OC43 infection in diverse adult populations","volume":"208","author":"Walsh","year":"2013","journal-title":"J. Infect. Dis."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115772_bib17","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.cll.2009.07.007","article-title":"Recently discovered human coronaviruses","volume":"29","author":"Wevers","year":"2009","journal-title":"Clin. Lab. Med."},{"issue":"8","key":"10.1016\/j.ejmech.2023.115772_bib18","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1086\/374222","article-title":"An outbreak of coronavirus OC43 respiratory infection in Normandy, France","volume":"36","author":"Vabret","year":"2003","journal-title":"Clin. Infect. Dis."},{"issue":"19","key":"10.1016\/j.ejmech.2023.115772_bib19","doi-asserted-by":"crossref","first-page":"8913","DOI":"10.1128\/JVI.74.19.8913-8921.2000","article-title":"Neuroinvasion by human respiratory coronaviruses","volume":"74","author":"Arbour","year":"2000","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115772_bib20","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1128\/JVI.73.4.3326-3337.1999","article-title":"Persistent infection of human oligodendrocytic and neuroglial cell lines by human coronavirus 229E","volume":"73","author":"Arbour","year":"1999","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115772_bib21","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.virol.2006.01.049","article-title":"Human coronavirus OC43 infection induces chronic encephalitis leading to disabilities in BALB\/C mice","volume":"349","author":"Jacomy","year":"2006","journal-title":"Virology"},{"issue":"3","key":"10.1016\/j.ejmech.2023.115772_bib22","first-page":"180","article-title":"Complete genome sequences of the SARS-CoV: the BJ group (isolates BJ01-BJ04)","volume":"1","author":"Bi","year":"2003","journal-title":"Dev. Reprod. Biol."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib23","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/22221751.2020.1719902","article-title":"Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan","volume":"9","author":"Chan","year":"2020","journal-title":"Emerg. Microb. Infect."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12985-019-1182-0","article-title":"Coronavirus envelope protein: current knowledge","volume":"16","author":"Schoeman","year":"2019","journal-title":"Virol. J."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115772_bib25","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.dsx.2020.04.020","article-title":"Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): an overview of viral structure and host response","volume":"14","author":"Astuti","year":"2020","journal-title":"Diabetes Metabol. Syndr.: Clin. Res. Rev."},{"issue":"11","key":"10.1016\/j.ejmech.2023.115772_bib26","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/cmdc.202000223","article-title":"Drug development and medicinal chemistry efforts toward SARS\u2010coronavirus and Covid\u201019 therapeutics","volume":"15","author":"Ghosh","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2023.115772_bib27","first-page":"183","article-title":"Progress in anti-SARS coronavirus chemistry, biology and chemotherapy","volume":"41","author":"Ghosh","year":"2006","journal-title":"Annu. Rep. Med. Chem."},{"issue":"1\u20132","key":"10.1016\/j.ejmech.2023.115772_bib28","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0014-5793(02)03640-2","article-title":"Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme","volume":"532","author":"Harmer","year":"2002","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejmech.2023.115772_bib29","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0065-3527(06)66005-3","article-title":"The molecular biology of coronaviruses","volume":"66","author":"Masters","year":"2006","journal-title":"Adv. Virus Res."},{"issue":"5626","key":"10.1016\/j.ejmech.2023.115772_bib30","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1126\/science.1085658","article-title":"Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs","volume":"300","author":"Anand","year":"2003","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.ejmech.2023.115772_bib31","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1021\/acs.jmedchem.2c01229","article-title":"Antitarget, anti-SARS-CoV-2 leads, drugs, and the drug discovery\u2013genetics alliance perspective","volume":"66","author":"Pozzi","year":"2023","journal-title":"J. Med. Chem."},{"issue":"6489","key":"10.1016\/j.ejmech.2023.115772_bib32","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.ejmech.2023.115772_bib33","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/0092-8674(94)90059-0","article-title":"Structure of human rhinovirus 3C protease reveals a trypsin-like polypeptide fold, RNA-binding site, and means for cleaving precursor polyprotein","volume":"77","author":"Matthews","year":"1994","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.ejmech.2023.115772_bib34","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0168-1702(99)00043-X","article-title":"The structures of picornaviral proteinases","volume":"62","author":"Seipelt","year":"1999","journal-title":"Virus Res."},{"issue":"8","key":"10.1016\/j.ejmech.2023.115772_bib35","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1021\/jm010469k","article-title":"Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 6. Structure\u2212 activity studies of orally bioavailable, 2-pyridone-containing peptidomimetics","volume":"45","author":"Dragovich","year":"2002","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2023.115772_bib36","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0960-894X(02)00008-2","article-title":"Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. Part 7: structure\u2013activity studies of bicyclic 2-pyridone-containing peptidomimetics","volume":"12","author":"Dragovich","year":"2002","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib37","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0960-894X(99)00587-9","article-title":"Structure-based design of ketone-containing, tripeptidyl human rhinovirus 3C protease inhibitors","volume":"10","author":"Dragovich","year":"2000","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"7","key":"10.1016\/j.ejmech.2023.115772_bib38","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1021\/jm9805384","article-title":"Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements","volume":"42","author":"Dragovich","year":"1999","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2023.115772_bib39","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1021\/jm980537b","article-title":"Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure\u2212 activity studies of ketomethylene-containing peptidomimetics","volume":"42","author":"Dragovich","year":"1999","journal-title":"J. Med. Chem."},{"issue":"7811","key":"10.1016\/j.ejmech.2023.115772_bib40","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"issue":"6497","key":"10.1016\/j.ejmech.2023.115772_bib41","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1126\/science.abb4489","article-title":"Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease","volume":"368","author":"Dai","year":"2020","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.ejmech.2023.115772_bib42","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1021\/acs.jmedchem.0c02258","article-title":"Design, synthesis, and biological evaluation of peptidomimetic aldehydes as broad-spectrum inhibitors against enterovirus and SARS-CoV-2","volume":"65","author":"Dai","year":"2021","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib43","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1038\/s41467-020-18096-2","article-title":"Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication","volume":"11","author":"Vuong","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib44","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1038\/s41467-020-18233-x","article-title":"Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease","volume":"11","author":"Fu","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib45","article-title":"Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors","volume":"12","author":"Iketani","year":"2021","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.ejmech.2023.115772_bib46","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00872-20","article-title":"Discovery of M protease inhibitors encoded by SARS-CoV-2","volume":"64","author":"Hung","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"10.1016\/j.ejmech.2023.115772_bib47","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41422-020-0356-z","article-title":"Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease","volume":"30","author":"Ma","year":"2020","journal-title":"Cell Res."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115772_bib48","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1021\/acsinfecdis.0c00761","article-title":"Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronaviruses","volume":"7","author":"Hu","year":"2021","journal-title":"ACS Infect. Dis."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib49","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/22221751.2021.1899770","article-title":"The preclinical inhibitor GS441524 in combination with GC376 efficaciously inhibited the proliferation of SARS-CoV-2 in the mouse respiratory tract","volume":"10","author":"Shi","year":"2021","journal-title":"Emerg. Microb. Infect."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib50","doi-asserted-by":"crossref","first-page":"9609","DOI":"10.1038\/s41598-021-89013-w","article-title":"Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model","volume":"11","author":"C\u00e1ceres","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2023.115772_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113584","article-title":"Improved SARS-CoV-2 Mpro inhibitors based on feline antiviral drug GC376: structural enhancements, increased solubility, and micellar studies","volume":"222","author":"Vuong","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"29","key":"10.1016\/j.ejmech.2023.115772_bib52","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2101555118","article-title":"Postinfection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection","volume":"118","author":"Dampalla","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"557","key":"10.1016\/j.ejmech.2023.115772_bib53","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc5332","article-title":"3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV\u2013infected mice","volume":"12","author":"Rathnayake","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"14","key":"10.1016\/j.ejmech.2023.115772_bib54","doi-asserted-by":"crossref","first-page":"10047","DOI":"10.1021\/acs.jmedchem.1c00319","article-title":"Structure-guided design of conformationally constrained cyclohexane inhibitors of severe acute respiratory syndrome coronavirus-2 3CL protease","volume":"64","author":"Dampalla","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115772_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115376","article-title":"Structure-guided design of direct-acting antivirals that exploit the gem-dimethyl effect and potently inhibit 3CL proteases of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) and middle east respiratory syndrome coronavirus (MERS-CoV)","volume":"254","author":"Dampalla","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"24","key":"10.1016\/j.ejmech.2023.115772_bib56","doi-asserted-by":"crossref","first-page":"17846","DOI":"10.1021\/acs.jmedchem.1c01037","article-title":"Structure-guided design of potent inhibitors of SARS-CoV-2 3CL protease: structural, biochemical, and cell-based studies","volume":"64","author":"Dampalla","year":"2021","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2023.115772_bib57","doi-asserted-by":"crossref","first-page":"7818","DOI":"10.1021\/acs.jmedchem.2c00224","article-title":"Structure-guided design of potent spirocyclic inhibitors of severe acute respiratory syndrome coronavirus-2 3C-like protease","volume":"65","author":"Dampalla","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115772_bib58","series-title":"Broad-Spectrum Cyclopropane-Based Inhibitors of Coronavirus 3C-like Proteases: Biochemical, Structural, and Virological Studies","author":"Dampalla","year":"2022"},{"key":"10.1016\/j.ejmech.2023.115772_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114458","article-title":"The structure-based design of peptidomimetic inhibitors against SARS-CoV-2 3C like protease as Potent anti-viral drug candidate","volume":"238","author":"Wang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib60","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1038\/s41467-022-29413-2","article-title":"Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19","volume":"13","author":"Liu","year":"2022","journal-title":"Nat. Commun."},{"issue":"6542","key":"10.1016\/j.ejmech.2023.115772_bib61","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1126\/science.abf7945","article-title":"X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease","volume":"372","author":"G\u00fcnther","year":"2021","journal-title":"Science"},{"issue":"16","key":"10.1016\/j.ejmech.2023.115772_bib62","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1021\/jm0603926","article-title":"Synthesis, crystal structure, structure\u2212 activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor","volume":"49","author":"Yang","year":"2006","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib63","article-title":"MPI8 is potent against SARS\u2010CoV\u20102 by inhibiting dually and selectively the SARS\u2010CoV\u20102 main protease and the host cathepsin L","volume":"17","author":"Ma","year":"2022","journal-title":"ChemMedChem"},{"issue":"6","key":"10.1016\/j.ejmech.2023.115772_bib64","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/cmdc.202000924","article-title":"A quick route to multiple highly potent SARS\u2010CoV\u20102 main protease inhibitors","volume":"16","author":"Yang","year":"2021","journal-title":"ChemMedChem"},{"issue":"4","key":"10.1016\/j.ejmech.2023.115772_bib65","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.apsb.2021.10.026","article-title":"Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays","volume":"12","author":"Ma","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"7","key":"10.1016\/j.ejmech.2023.115772_bib66","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/cbic.200500533","article-title":"An efficient method for the synthesis of peptide aldehyde libraries employed in the discovery of reversible SARS coronavirus main protease (SARS\u2010CoV Mpro) inhibitors","volume":"7","author":"Al\u2010Gharabli","year":"2006","journal-title":"Chembiochem"},{"issue":"2","key":"10.1016\/j.ejmech.2023.115772_bib67","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.antiviral.2011.08.001","article-title":"Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease","volume":"92","author":"Zhu","year":"2011","journal-title":"Antivir. Res."},{"issue":"21","key":"10.1016\/j.ejmech.2023.115772_bib68","doi-asserted-by":"crossref","first-page":"9400","DOI":"10.1016\/j.bmc.2008.09.057","article-title":"Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant","volume":"16","author":"Akaji","year":"2008","journal-title":"Bioorg. Med. Chem."},{"issue":"23","key":"10.1016\/j.ejmech.2023.115772_bib69","doi-asserted-by":"crossref","first-page":"7962","DOI":"10.1021\/jm200870n","article-title":"Structure-based design, synthesis, and evaluation of peptide-mimetic SARS 3CL protease inhibitors","volume":"54","author":"Akaji","year":"2011","journal-title":"J. Med. Chem."},{"issue":"6536","key":"10.1016\/j.ejmech.2023.115772_bib70","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1126\/science.abf1611","article-title":"SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model","volume":"371","author":"Qiao","year":"2021","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.ejmech.2023.115772_bib71","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1021\/acsptsci.1c00099","article-title":"Rational design of hybrid SARS-CoV-2 main protease inhibitors guided by the superimposed cocrystal structures with the peptidomimetic inhibitors GC-376, telaprevir, and boceprevir","volume":"4","author":"Xia","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"50","key":"10.1016\/j.ejmech.2023.115772_bib72","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe0751","article-title":"Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against Mpro and cathepsin L","volume":"6","author":"Sacco","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2023.115772_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114570","article-title":"A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antivirals","volume":"240","author":"Ma","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"21","key":"10.1016\/j.ejmech.2023.115772_bib74","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111779","article-title":"Structural and biochemical analysis of the dual inhibition of MG-132 against SARS-CoV-2 main protease (Mpro\/3CLpro) and human cathepsin-L","volume":"22","author":"Costanzi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2023.115772_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114596","article-title":"A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals","volume":"240","author":"Alugubelli","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115772_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115311","article-title":"Broad-spectrum coronavirus 3C-like protease peptidomimetic inhibitors effectively block SARS-CoV-2 replication in cells: design, synthesis, biological evaluation, and X-ray structure determination","volume":"253","author":"Stefanelli","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2023.115772_bib77","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1016\/j.bmcl.2009.03.118","article-title":"New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CLpro inhibitors","volume":"19","author":"Regnier","year":"2009","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"2","key":"10.1016\/j.ejmech.2023.115772_bib78","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.bmc.2012.11.017","article-title":"Design and synthesis of new tripeptide-type SARS-CoV 3CL protease inhibitors containing an electrophilic arylketone moiety","volume":"21","author":"Konno","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115772_bib79","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ejmech.2013.05.005","article-title":"Design, synthesis, and biological evaluation of novel dipeptide-type SARS-CoV 3CL protease inhibitors: structure\u2013activity relationship study","volume":"65","author":"Thanigaimalai","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115772_bib80","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.ejmech.2013.07.037","article-title":"Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: design, synthesis, biological evaluation, and docking studies","volume":"68","author":"Thanigaimalai","year":"2013","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib81","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/s41467-021-20900-6","article-title":"A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication","volume":"12","author":"Hattori","year":"2021","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115772_bib82","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1021\/acs.jmedchem.1c00665","article-title":"3CL protease inhibitors with an electrophilic arylketone moiety as anti-SARS-CoV-2 agents","volume":"65","author":"Konno","year":"2021","journal-title":"J. Med. Chem."},{"issue":"21","key":"10.1016\/j.ejmech.2023.115772_bib83","doi-asserted-by":"crossref","first-page":"12725","DOI":"10.1021\/acs.jmedchem.0c01063","article-title":"Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19","volume":"63","author":"Hoffman","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115772_bib84","series-title":"Discovery of a Novel Inhibitor of Coronavirus 3CL Protease as a Clinical Candidate for the Potential Treatment of COVID-19 (Preprint)","author":"Boras","year":"2020"},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib85","doi-asserted-by":"crossref","first-page":"6055","DOI":"10.1038\/s41467-021-26239-2","article-title":"Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19","volume":"12","author":"Boras","year":"2021","journal-title":"Nat. Commun."},{"issue":"6575","key":"10.1016\/j.ejmech.2023.115772_bib86","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.ejmech.2023.115772_bib87","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1021\/acsmedchemlett.2c00260","article-title":"A warhead substitution study on the coronavirus main protease inhibitor nirmatrelvir","volume":"13","author":"Vankadara","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115772_bib88","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1021\/acs.jmedchem.1c00616","article-title":"Peptidomimetic \u03b1-acyloxymethylketone warheads with six-membered lactam P1 glutamine mimic: SARS-CoV-2 3CL protease inhibition, coronavirus antiviral activity, and in vitro biological stability","volume":"65","author":"Bai","year":"2021","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2023.115772_bib89","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1021\/acsinfecdis.0c00815","article-title":"Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID-19","volume":"7","author":"Steuten","year":"2021","journal-title":"ACS Infect. Dis."},{"issue":"9","key":"10.1016\/j.ejmech.2023.115772_bib90","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1021\/acs.jmedchem.9b01828","article-title":"\u03b1-Ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: structure-based design, synthesis, and activity assessment","volume":"63","author":"Zhang","year":"2020","journal-title":"J. Med. Chem."},{"issue":"19","key":"10.1016\/j.ejmech.2023.115772_bib91","doi-asserted-by":"crossref","first-page":"13328","DOI":"10.1021\/acs.jmedchem.2c01131","article-title":"Diastereomeric resolution yields highly potent inhibitor of SARS-CoV-2 main protease","volume":"65","author":"Cooper","year":"2022","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2023.115772_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109133","article-title":"Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture","volume":"35","author":"Bafna","year":"2021","journal-title":"Cell Rep."},{"issue":"12","key":"10.1016\/j.ejmech.2023.115772_bib93","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1021\/acsmedchemlett.0c00521","article-title":"Identification of 14 known drugs as inhibitors of the main protease of SARS-CoV-2","volume":"11","author":"Ghahremanpour","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115772_bib94","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1039\/D0MD00367K","article-title":"Repurposing the HCV NS3\u20134A protease drug boceprevir as COVID-19 therapeutics","volume":"12","author":"Oerlemans","year":"2021","journal-title":"RSC Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115772_bib95","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0245962","article-title":"A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease","volume":"16","author":"Baker","year":"2021","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.ejmech.2023.115772_bib96","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.str.2020.10.007","article-title":"Malleability of the SARS-CoV-2 3CL Mpro active-site cavity facilitates binding of clinical antivirals","volume":"28","author":"Kneller","year":"2020","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2023.115772_bib97","series-title":"Rational Design of a New Class of Protease Inhibitors for the Potential Treatment of Coronavirus Diseases","author":"Westberg","year":"2020"},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib98","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41392-021-00468-9","article-title":"Structural basis for the inhibition of the SARS-CoV-2 main protease by the anti-HCV drug narlaprevir","volume":"6","author":"Bai","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib99","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41392-023-01392-w","article-title":"A new generation Mpro inhibitor with potent activity against SARS-CoV-2 Omicron variants","volume":"8","author":"Huang","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"5","key":"10.1016\/j.ejmech.2023.115772_bib100","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/s41564-022-01119-7","article-title":"An orally available Mpro inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron","volume":"7","author":"Quan","year":"2022","journal-title":"Nature Microbiology"},{"issue":"25","key":"10.1016\/j.ejmech.2023.115772_bib101","doi-asserted-by":"crossref","first-page":"6113","DOI":"10.1021\/jm0494873","article-title":"Synthesis and evaluation of keto-glutamine analogues as potent inhibitors of severe acute respiratory syndrome 3CLpro","volume":"47","author":"Jain","year":"2004","journal-title":"J. Med. Chem."},{"issue":"36","key":"10.1016\/j.ejmech.2023.115772_bib102","doi-asserted-by":"crossref","first-page":"8601","DOI":"10.1016\/j.tet.2006.06.052","article-title":"Synthesis of glutamic acid and glutamine peptides possessing a trifluoromethyl ketone group as SARS-CoV 3CL protease inhibitors","volume":"62","author":"Sydnes","year":"2006","journal-title":"Tetrahedron"},{"issue":"8","key":"10.1016\/j.ejmech.2023.115772_bib103","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1016\/j.bmc.2008.02.040","article-title":"Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease","volume":"16","author":"Shao","year":"2008","journal-title":"Bioorg. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib104","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0006-291X(03)01342-1","article-title":"Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS","volume":"308","author":"Chou","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"17","key":"10.1016\/j.ejmech.2023.115772_bib105","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.1016\/j.bmc.2005.05.065","article-title":"Inhibition of the severe acute respiratory syndrome 3CL protease by peptidomimetic \u03b1, \u03b2-unsaturated esters","volume":"13","author":"Shie","year":"2005","journal-title":"Bioorg. Med. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2023.115772_bib106","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2012201118","article-title":"Bepridil is potent against SARS-CoV-2 in vitro","volume":"118","author":"Vatansever","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib107","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1038\/s41467-020-19055-7","article-title":"A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19","volume":"11","author":"Xie","year":"2020","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.ejmech.2023.115772_bib108","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1371\/journal.pbio.0030324","article-title":"Design of wide-spectrum inhibitors targeting coronavirus main proteases","volume":"3","author":"Yang","year":"2005","journal-title":"PLoS Biol."},{"issue":"12","key":"10.1016\/j.ejmech.2023.115772_bib109","doi-asserted-by":"crossref","first-page":"7646","DOI":"10.1074\/jbc.M807947200","article-title":"Structural basis of inhibition specificities of 3C and 3C-like proteases by zinc-coordinating and peptidomimetic compounds","volume":"284","author":"Lee","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"46","key":"10.1016\/j.ejmech.2023.115772_bib110","doi-asserted-by":"crossref","first-page":"21035","DOI":"10.1021\/jacs.2c04626","article-title":"Dual inhibitors of main protease (MPro) and cathepsin L as potent antivirals against SARS-CoV2","volume":"144","author":"Mondal","year":"2022","journal-title":"J. Am. Chem. Soc."},{"issue":"22","key":"10.1016\/j.ejmech.2023.115772_bib111","doi-asserted-by":"crossref","first-page":"6767","DOI":"10.1021\/jm050548m","article-title":"Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors","volume":"48","author":"Ghosh","year":"2005","journal-title":"J. Med. Chem."},{"issue":"21","key":"10.1016\/j.ejmech.2023.115772_bib112","doi-asserted-by":"crossref","first-page":"5876","DOI":"10.1016\/j.bmcl.2007.08.031","article-title":"Structure-based design, synthesis, and biological evaluation of peptidomimetic SARS-CoV 3CLpro inhibitors","volume":"17","author":"Ghosh","year":"2007","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"4","key":"10.1016\/j.ejmech.2023.115772_bib113","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1021\/acs.jcim.1c00184","article-title":"Lead discovery of SARS-CoV-2 main protease inhibitors through covalent docking-based virtual screening","volume":"61","author":"Amendola","year":"2021","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2023.115772_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.115021","article-title":"Structure-based lead optimization of peptide-based vinyl methyl ketones as SARS-CoV-2 main protease inhibitors","volume":"247","author":"Previti","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115772_bib115","series-title":"An Azapeptide Platform in Conjunction with Covalent Warheads to Uncover High-Potency Inhibitors for SARS-CoV-2 Main Protease","author":"Khatua","year":"2023"},{"issue":"12","key":"10.1016\/j.ejmech.2023.115772_bib116","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/j.chembiol.2021.05.018","article-title":"An automatic pipeline for the design of irreversible derivatives identifies a potent SARS-CoV-2 Mpro inhibitor","volume":"28","author":"Zaidman","year":"2021","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115772_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114046","article-title":"Design, synthesis and in vitro evaluation of novel SARS-CoV-2 3CLpro covalent inhibitors","volume":"229","author":"Stille","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115772_bib118","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41589-020-00689-z","article-title":"SARS-CoV-2 Mpro inhibitors and activity-based probes for patient-sample imaging","volume":"17","author":"Rut","year":"2021","journal-title":"Nat. Chem. Biol."},{"issue":"49","key":"10.1016\/j.ejmech.2023.115772_bib119","doi-asserted-by":"crossref","first-page":"20697","DOI":"10.1021\/jacs.1c08060","article-title":"Discovery of di-and trihaloacetamides as covalent SARS-CoV-2 main protease inhibitors with high target specificity","volume":"143","author":"Ma","year":"2021","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2023.115772_bib120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113863","article-title":"Identification of a dual acting SARS-CoV-2 proteases inhibitor through in silico design and step-by-step biological characterization","volume":"226","author":"Di Sarno","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"23","key":"10.1016\/j.ejmech.2023.115772_bib121","doi-asserted-by":"crossref","first-page":"13190","DOI":"10.1073\/pnas.1835675100","article-title":"The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor","volume":"100","author":"Yang","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib122","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1747-0285.2008.00679.x","article-title":"Development of broad\u2010spectrum halomethyl ketone inhibitors against coronavirus main protease 3CLpro","volume":"72","author":"Bacha","year":"2008","journal-title":"Chem. Biol. Drug Des."},{"issue":"10","key":"10.1016\/j.ejmech.2023.115772_bib123","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1039\/D1SC06596C","article-title":"Selective covalent targeting of SARS-CoV-2 main protease by enantiopure chlorofluoroacetamide","volume":"13","author":"Yamane","year":"2022","journal-title":"Chem. Sci."},{"issue":"13","key":"10.1016\/j.ejmech.2023.115772_bib124","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1042\/BCJ20210197","article-title":"Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp5 main protease","volume":"478","author":"Milligan","year":"2021","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2023.115772_bib125","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.reprotox.2022.01.006","article-title":"Reproductive and developmental safety of nirmatrelvir (PF-07321332), an oral SARS-CoV-2 Mpro inhibitor in animal models","volume":"108","author":"Catlin","year":"2022","journal-title":"Reprod. Toxicol."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib126","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1038\/s41467-022-29915-z","article-title":"Covalent narlaprevir-and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease","volume":"13","author":"Kneller","year":"2022","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.ejmech.2023.115772_bib127","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1039\/D1MD00247C","article-title":"Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors","volume":"12","author":"Bai","year":"2021","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115772_bib128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2012.10.053","article-title":"Design, synthesis and crystallographic analysis of nitrile-based broad-spectrum peptidomimetic inhibitors for coronavirus 3C-like proteases","volume":"59","author":"Chuck","year":"2013","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115772_bib129","first-page":"22","article-title":"Profiling of substrate-specificity and rational design of broadspectrum peptidomimetic inhibitors for main proteases of coronaviruses","volume":"20","author":"Chuck","year":"2014","journal-title":"Hong Kong Med. J."},{"issue":"18","key":"10.1016\/j.ejmech.2023.115772_bib130","doi-asserted-by":"crossref","first-page":"10423","DOI":"10.1002\/anie.202016961","article-title":"Targeting the main protease of SARS\u2010CoV\u20102: from the establishment of high throughput screening to the design of tailored inhibitors","volume":"60","author":"Breidenbach","year":"2021","journal-title":"Angew. Chem. Int. Ed."},{"issue":"30","key":"10.1016\/j.ejmech.2023.115772_bib131","doi-asserted-by":"crossref","first-page":"8744","DOI":"10.1021\/bi0621415","article-title":"Substrate specificity profiling and identification of a new class of inhibitor for the major protease of the SARS coronavirus","volume":"46","author":"Goetz","year":"2007","journal-title":"Biochemistry"},{"issue":"4","key":"10.1016\/j.ejmech.2023.115772_bib132","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.peptides.2005.09.006","article-title":"Synthesis and activity of an octapeptide inhibitor designed for SARS coronavirus main proteinase","volume":"27","author":"Gan","year":"2006","journal-title":"Peptides"},{"issue":"3","key":"10.1016\/j.ejmech.2023.115772_bib133","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.bbrc.2005.11.102","article-title":"The N-terminal octapeptide acts as a dimerization inhibitor of SARS coronavirus 3C-like proteinase","volume":"339","author":"Wei","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"27","key":"10.1016\/j.ejmech.2023.115772_bib134","doi-asserted-by":"crossref","first-page":"10012","DOI":"10.1073\/pnas.0403596101","article-title":"Small molecules targeting severe acute respiratory syndrome human coronavirus","volume":"101","author":"Wu","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"14","key":"10.1016\/j.ejmech.2023.115772_bib135","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/cbic.200700254","article-title":"Structure\u2010based design and synthesis of highly potent SARS\u2010CoV 3CL protease inhibitors","volume":"8","author":"Shao","year":"2007","journal-title":"Chembiochem"},{"issue":"24","key":"10.1016\/j.ejmech.2023.115772_bib136","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.1016\/j.bmcl.2005.09.012","article-title":"Screening of electrophilic compounds yields an aziridinyl peptide as new active-site directed SARS-CoV main protease inhibitor","volume":"15","author":"Martina","year":"2005","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"5","key":"10.1016\/j.ejmech.2023.115772_bib137","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.jmb.2005.09.004","article-title":"Crystal structures of the main peptidase from the SARS coronavirus inhibited by a substrate-like aza-peptide epoxide","volume":"353","author":"Lee","year":"2005","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2023.115772_bib138","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1016\/j.ijbiomac.2020.08.166","article-title":"Screening and evaluation of approved drugs as inhibitors of main protease of SARS-CoV-2","volume":"164","author":"Tripathi","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"issue":"6","key":"10.1016\/j.ejmech.2023.115772_bib139","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.bmc.2016.01.052","article-title":"Design and synthesis of a series of serine derivatives as small molecule inhibitors of the SARS coronavirus 3CL protease","volume":"24","author":"Konno","year":"2016","journal-title":"Bioorg. Med. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2023.115772_bib140","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1016\/j.bmcl.2017.04.056","article-title":"Synthesis and evaluation of phenylisoserine derivatives for the SARS-CoV 3CL protease inhibitor","volume":"27","author":"Konno","year":"2017","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"2","key":"10.1016\/j.ejmech.2023.115772_bib141","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1021\/jm301580n","volume":"56","author":"Jacobs","year":"2013","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115772_bib142","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3390\/v13020174","article-title":"Crystal structure of SARS-CoV-2 main protease in complex with the non-covalent inhibitor ML188","volume":"13","author":"Lockbaum","year":"2021","journal-title":"Viruses"},{"issue":"4","key":"10.1016\/j.ejmech.2023.115772_bib143","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1021\/acs.jmedchem.1c00509","article-title":"Expedited approach toward the rational design of noncovalent SARS-CoV-2 main protease inhibitors","volume":"65","author":"Kitamura","year":"2021","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2023.115772_bib144","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00825-20","article-title":"Atazanavir, alone or in combination with ritonavir, inhibits SARS-CoV-2 replication and proinflammatory cytokine production","volume":"64","author":"Fintelman-Rodrigues","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib145","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/ph15010021","article-title":"Atazanavir is a competitive inhibitor of SARS-CoV-2 Mpro, impairing variants replication in vitro and in vivo","volume":"15","author":"Chaves","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"51","key":"10.1016\/j.ejmech.2023.115772_bib146","doi-asserted-by":"crossref","first-page":"33151","DOI":"10.1021\/acsomega.0c04808","article-title":"Structure-based virtual screening and biochemical validation to discover a potential inhibitor of the SARS-CoV-2 main protease","volume":"5","author":"Gupta","year":"2020","journal-title":"ACS Omega"},{"issue":"8","key":"10.1016\/j.ejmech.2023.115772_bib147","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2024420118","article-title":"Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors","volume":"118","author":"Ma","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.ejmech.2023.115772_bib148","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3390\/ph14030178","article-title":"Evaluation of the antiviral activity of sitagliptin-glatiramer acetate nano-conjugates against SARS-CoV-2 virus","volume":"14","author":"Alhakamy","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2023.115772_bib149","series-title":"Discovery of Baicalin and Baicalein as Novel, Natural Product Inhibitors of SARS-CoV-2 3CL Protease in Vitro","author":"Su","year":"2020"},{"issue":"9","key":"10.1016\/j.ejmech.2023.115772_bib150","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41401-020-0483-6","article-title":"Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients","volume":"41","author":"Su","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib151","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/14756366.2021.1873977","article-title":"Scutellaria baicalensis extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease in vitro","volume":"36","author":"Liu","year":"2021","journal-title":"J. Enzym. Inhib. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib152","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1038\/s41467-021-23751-3","article-title":"Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease","volume":"12","author":"Su","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115772_bib153","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.ijbiomac.2021.07.167","article-title":"Flavonoids in Ampelopsis grossedentata as covalent inhibitors of SARS-CoV-2 3CLpro: inhibition potentials, covalent binding sites and inhibitory mechanisms","volume":"187","author":"Xiong","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejmech.2023.115772_bib154","series-title":"Development of a Red-Shifted Fluorescence-Based Assay for SARS-Coronavirus 3CL Protease: Identification of a Novel Class of Anti-SARS Agents from the Tropical Marine Sponge Axinella Corrugata","author":"Hamill","year":"2006"},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib155","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.antiviral.2005.07.002","article-title":"Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds","volume":"68","author":"Lin","year":"2005","journal-title":"Antivir. Res."},{"issue":"22","key":"10.1016\/j.ejmech.2023.115772_bib156","doi-asserted-by":"crossref","first-page":"7940","DOI":"10.1016\/j.bmc.2010.09.035","article-title":"Biflavonoids from Torreya nucifera displaying SARS-CoV 3CLpro inhibition","volume":"18","author":"Ryu","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115772_bib157","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s10529-011-0845-8","article-title":"Flavonoid-mediated inhibition of SARS coronavirus 3C-like protease expressed in Pichia pastoris","volume":"34","author":"Nguyen","year":"2012","journal-title":"Biotechnol. Lett."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib158","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/14756366.2019.1690480","article-title":"Inhibition of SARS-CoV 3CL protease by flavonoids","volume":"35","author":"Jo","year":"2020","journal-title":"J. Enzym. Inhib. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib159","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1080\/14756366.2020.1801672","article-title":"Flavonoids with inhibitory activity against SARS-CoV-2 3CLpro","volume":"35","author":"Jo","year":"2020","journal-title":"J. Enzym. Inhib. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115772_bib160","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/ecam\/neh081","article-title":"Inhibition of SARS-CoV 3C-like protease activity by theaflavin-3, 3'-digallate (TF3)","volume":"2","author":"Chen","year":"2005","journal-title":"Evid. base Compl. Alternative Med."},{"key":"10.1016\/j.ejmech.2023.115772_bib161","series-title":"Tea Polyphenols EGCG and Theaflavin Inhibit the Activity of SARS-CoV-2 3CL-Protease in Vitro","author":"Jang","year":"2020"},{"key":"10.1016\/j.ejmech.2023.115772_bib162","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijbiomac.2021.02.012","article-title":"Epigallocatechin-3-gallate, an active ingredient of Traditional Chinese Medicines, inhibits the 3CLpro activity of SARS-CoV-2","volume":"176","author":"Du","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejmech.2023.115772_bib163","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.bbrc.2020.12.106","article-title":"The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease","volume":"591","author":"Chiou","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"24","key":"10.1016\/j.ejmech.2023.115772_bib164","doi-asserted-by":"crossref","first-page":"8295","DOI":"10.1016\/j.bmc.2006.09.014","article-title":"Binding interaction of quercetin-3-\u03b2-galactoside and its synthetic derivatives with SARS-CoV 3CLpro: structure\u2013activity relationship studies reveal salient pharmacophore features","volume":"14","author":"Chen","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115772_bib165","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/j.ijbiomac.2020.07.235","article-title":"Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening","volume":"164","author":"Abian","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"issue":"8","key":"10.1016\/j.ejmech.2023.115772_bib166","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1177\/1087057106293295","article-title":"Discovering severe acute respiratory syndrome coronavirus 3CL protease inhibitors: virtual screening, surface plasmon resonance, and fluorescence resonance energy transfer assays","volume":"11","author":"Chen","year":"2006","journal-title":"Slas Discovery"},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib167","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/14756366.2014.1003215","article-title":"Chalcones isolated from Angelica keiskei inhibit cysteine proteases of SARS-CoV","volume":"31","author":"Park","year":"2016","journal-title":"J. Enzym. Inhib. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115772_bib168","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3390\/ph14030213","article-title":"Repurposing of some natural product isolates as SARS-COV-2 main protease inhibitors via in vitro cell free and cell-based antiviral assessments and molecular modeling approaches","volume":"14","author":"Abdallah","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"4","key":"10.1016\/j.ejmech.2023.115772_bib169","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3390\/biomedicines9040375","article-title":"Rutin is a low micromolar inhibitor of SARS-CoV-2 main protease 3CLpro: implications for drug design of quercetin analogs","volume":"9","author":"Rizzuti","year":"2021","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.ejmech.2023.115772_bib170","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3390\/ph14060541","article-title":"Scaffold hopping of \u03b1-Rubromycin enables direct access to FDA-approved cromoglicic acid as a SARS-CoV-2 MPro inhibitor","volume":"14","author":"Alhadrami","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2023.115772_bib171","doi-asserted-by":"crossref","DOI":"10.1016\/j.fitote.2021.104909","article-title":"Discovery of naturally occurring inhibitors against SARS-CoV-2 3CLpro from Ginkgo biloba leaves via large-scale screening","volume":"152","author":"Xiong","year":"2021","journal-title":"Fitoterapia"},{"key":"10.1016\/j.ejmech.2023.115772_bib172","series-title":"Open Science Discovery of Oral Non-covalent SARS-CoV-2 Main Protease Inhibitor Therapeutics","author":"Consortium","year":"2020"},{"issue":"5","key":"10.1016\/j.ejmech.2023.115772_bib173","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1021\/acsptsci.0c00108","article-title":"Identification of SARS-CoV-2 3CL protease inhibitors by a quantitative high-throughput screening","volume":"3","author":"Zhu","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"7","key":"10.1016\/j.ejmech.2023.115772_bib174","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1021\/jacs.1c08402","article-title":"Ultralarge virtual screening identifies SARS-CoV-2 main protease inhibitors with broad-spectrum activity against coronaviruses","volume":"144","author":"Luttens","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2023.115772_bib175","article-title":"Discovery of quinazolin-4-one-based non-covalent inhibitors targeting the severe acute respiratory syndrome coronavirus 2 main protease (SARS-CoV-2 Mpro)","author":"Zhang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2023.115772_bib176","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009898","article-title":"Ethacridine inhibits SARS-CoV-2 by inactivating viral particles","volume":"17","author":"Li","year":"2021","journal-title":"PLoS Pathog."},{"issue":"5","key":"10.1016\/j.ejmech.2023.115772_bib177","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1021\/acscentsci.0c01186","article-title":"Simeprevir potently suppresses SARS-CoV-2 replication and synergizes with remdesivir","volume":"7","author":"Lo","year":"2021","journal-title":"ACS Cent. Sci."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115772_bib178","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.bbrc.2004.04.083","article-title":"HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus","volume":"318","author":"Yamamoto","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2023.115772_bib179","series-title":"Nelfinavir Inhibits Replication of Severe Acute Respiratory Syndrome Coronavirus 2 in Vitro","author":"Yamamoto","year":"2020"},{"issue":"5","key":"10.1016\/j.ejmech.2023.115772_bib180","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2021579118","article-title":"Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection","volume":"118","author":"Jan","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib181","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1038\/s41467-021-23328-0","article-title":"Drug repurposing screens identify chemical entities for the development of COVID-19 interventions","volume":"12","author":"Bakowski","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115772_bib182","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115226","article-title":"Korupensamine A, but not its atropisomer, korupensamine B, inhibits SARS-CoV-2 in vitro by targeting its main protease (Mpro)","volume":"251","author":"Sayed","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115772_bib183","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.febslet.2008.12.059","article-title":"Individual and common inhibitors of coronavirus and picornavirus main proteases","volume":"583","author":"Kuo","year":"2009","journal-title":"FEBS Lett."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib184","doi-asserted-by":"crossref","first-page":"87","DOI":"10.5012\/bkcs.2010.31.01.087","article-title":"Synthesis and evaluation of benzoquinolinone derivatives as sars-cov 3cl protease inhibitors","volume":"31","author":"Ahn","year":"2010","journal-title":"Bull. Kor. Chem. Soc."},{"key":"10.1016\/j.ejmech.2023.115772_bib185","series-title":"Computationally Driven Discovery of SARS-CoV-2 Mpro Inhibitors: from Design to Experimental Validation (Preprint)","author":"Khoury","year":"2021"},{"issue":"44","key":"10.1016\/j.ejmech.2023.115772_bib186","doi-asserted-by":"crossref","first-page":"27381","DOI":"10.1073\/pnas.2010470117","article-title":"Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs","volume":"117","author":"Li","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.ejmech.2023.115772_bib187","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.bmc.2014.12.028","article-title":"Fused-ring structure of decahydroisoquinolin as a novel scaffold for SARS 3CL protease inhibitors","volume":"23","author":"Shimamoto","year":"2015","journal-title":"Bioorg. Med. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2023.115772_bib188","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/cjoc.201300392","article-title":"Synthesis and biological evaluation of quinolinone compounds as SARS CoV 3CLpro inhibitors","volume":"31","author":"Sun","year":"2013","journal-title":"Chin. J. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2023.115772_bib189","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1016\/j.bmc.2008.01.011","article-title":"Structure-based virtual screening against SARS-3CLpro to identify novel non-peptidic hits","volume":"16","author":"Mukherjee","year":"2008","journal-title":"Bioorg. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2023.115772_bib190","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1021\/ci1004916","article-title":"Inhibitors of SARS-3CLpro: virtual screening, biological evaluation, and molecular dynamics simulation studies","volume":"51","author":"Mukherjee","year":"2011","journal-title":"J. Chem. Inf. Model."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115772_bib191","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2019.115273","article-title":"Evaluation of an octahydroisochromene scaffold used as a novel SARS 3CL protease inhibitor","volume":"28","author":"Yoshizawa","year":"2020","journal-title":"Bioorg. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115772_bib192","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.bmc.2018.12.019","article-title":"Evaluation of a non-prime site substituent and warheads combined with a decahydroisoquinolin scaffold as a SARS 3CL protease inhibitor","volume":"27","author":"Ohnishi","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115772_bib193","series-title":"High-throughput Screening and Experimental Identification of Potent Drugs Targeting SARS-CoV-2 Main Protease","author":"Li","year":"2020"},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib194","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-022-06306-4","article-title":"Non-covalent SARS-CoV-2 Mpro inhibitors developed from in silico screen hits","volume":"12","author":"Rossetti","year":"2022","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib195","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41392-021-00628-x","article-title":"Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease","volume":"6","author":"Sun","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115772_bib196","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1021\/acs.jnatprod.1c00805","article-title":"Target-based virtual screening and LC\/MS-guided isolation procedure for identifying phloroglucinol-terpenoid inhibitors of SARS-CoV-2","volume":"85","author":"Hou","year":"2022","journal-title":"J. Nat. Prod."},{"issue":"17","key":"10.1016\/j.ejmech.2023.115772_bib197","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1021\/jm070295s","article-title":"Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus","volume":"50","author":"Wen","year":"2007","journal-title":"J. Med. Chem."},{"issue":"9374","key":"10.1016\/j.ejmech.2023.115772_bib198","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1016\/S0140-6736(03)13615-X","article-title":"Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus","volume":"361","author":"Cinatl","year":"2003","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ejmech.2023.115772_bib199","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3390\/v13040609","article-title":"Glycyrrhizin effectively inhibits SARS-CoV-2 replication by inhibiting the viral main protease","volume":"13","author":"van de Sand","year":"2021","journal-title":"Viruses"},{"issue":"6","key":"10.1016\/j.ejmech.2023.115772_bib200","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/j.bmcl.2010.01.152","article-title":"SARS-CoV 3CLpro inhibitory effects of quinone-methide triterpenes from Tripterygium regelii","volume":"20","author":"Ryu","year":"2010","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"3","key":"10.1016\/j.ejmech.2023.115772_bib201","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.bbrc.2020.08.086","article-title":"Andrographolide and its fluorescent derivative inhibit the main proteases of 2019-nCoV and SARS-CoV through covalent linkage","volume":"533","author":"Shi","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"5","key":"10.1016\/j.ejmech.2023.115772_bib202","article-title":"Andrographolide derivatives target the KEAP1\/NRF2 axis and possess potent anti\u2010SARS\u2010CoV\u20102 activity","volume":"17","author":"Schulte","year":"2022","journal-title":"ChemMedChem"},{"issue":"9","key":"10.1016\/j.ejmech.2023.115772_bib203","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.3390\/molecules26092654","article-title":"Olive-derived triterpenes suppress SARS COV-2 main protease: a promising scaffold for future therapeutics","volume":"26","author":"Alhadrami","year":"2021","journal-title":"Molecules"},{"issue":"20","key":"10.1016\/j.ejmech.2023.115772_bib204","doi-asserted-by":"crossref","first-page":"5684","DOI":"10.1016\/j.bmcl.2008.08.082","article-title":"Design, synthesis and antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors","volume":"18","author":"Ghosh","year":"2008","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"19","key":"10.1016\/j.ejmech.2023.115772_bib205","doi-asserted-by":"crossref","first-page":"14702","DOI":"10.1021\/acs.jmedchem.1c01214","article-title":"Indole chloropyridinyl ester-derived SARS-CoV-2 3CLpro inhibitors: enzyme inhibition, antiviral efficacy, structure\u2013activity relationship, and X-ray structural studies","volume":"64","author":"Ghosh","year":"2021","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115772_bib206","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01833-20","article-title":"GRL-0920, an indole chloropyridinyl ester, completely blocks SARS-CoV-2 infection","volume":"11","author":"Hattori","year":"2020","journal-title":"mBio"},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib207","first-page":"17","article-title":"High-throughput screening of SARS-CoV-2 main and papain-like protease inhibitors","volume":"14","author":"Zang","year":"2023","journal-title":"Protein & Cell"},{"issue":"3","key":"10.1016\/j.ejmech.2023.115772_bib208","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.chembiol.2005.12.008","article-title":"Stable benzotriazole esters as mechanism-based inactivators of the severe acute respiratory syndrome 3CL protease","volume":"13","author":"Wu","year":"2006","journal-title":"Chem. Biol."},{"issue":"10","key":"10.1016\/j.ejmech.2023.115772_bib209","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.chembiol.2004.08.011","article-title":"High-throughput screening identifies inhibitors of the SARS coronavirus main proteinase","volume":"11","author":"Blanchard","year":"2004","journal-title":"Chem. Biol."},{"issue":"8","key":"10.1016\/j.ejmech.2023.115772_bib210","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1021\/jm061425k","article-title":"Design, synthesis, and evaluation of inhibitors for severe acute respiratory syndrome 3C-like protease based on phthalhydrazide ketones or heteroaromatic esters","volume":"50","author":"Zhang","year":"2007","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib211","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.bmc.2007.09.034","article-title":"Molecular docking identifies the binding of 3-chloropyridine moieties specifically to the S1 pocket of SARS-CoV Mpro","volume":"16","author":"Niu","year":"2008","journal-title":"Bioorg. Med. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2023.115772_bib212","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.bioorg.2008.01.001","article-title":"Aryl methylene ketones and fluorinated methylene ketones as reversible inhibitors for severe acute respiratory syndrome (SARS) 3C-like proteinase","volume":"36","author":"Zhang","year":"2008","journal-title":"Bioorg. Chem."},{"issue":"19","key":"10.1016\/j.ejmech.2023.115772_bib213","doi-asserted-by":"crossref","first-page":"5782","DOI":"10.3390\/molecules26195782","article-title":"Chloropyridinyl esters of nonsteroidal anti-inflammatory agents and related derivatives as potent SARS-CoV-2 3CL protease inhibitors","volume":"26","author":"Ghosh","year":"2021","journal-title":"Molecules"},{"issue":"13","key":"10.1016\/j.ejmech.2023.115772_bib214","doi-asserted-by":"crossref","first-page":"9376","DOI":"10.1021\/acs.jmedchem.2c00636","article-title":"Small-molecule thioesters as SARS-CoV-2 main protease inhibitors: enzyme inhibition, structure\u2013activity relationships, antiviral activity, and X-ray structure determination","volume":"65","author":"Pillaiyar","year":"2022","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2023.115772_bib215","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.chembiol.2008.04.011","article-title":"A structural view of the inactivation of the SARS coronavirus main proteinase by benzotriazole esters","volume":"15","author":"Verschueren","year":"2008","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115772_bib216","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115186","article-title":"Novel dithiocarbamates selectively inhibit 3CL protease of SARS-CoV-2 and other coronaviruses","volume":"250","author":"Brier","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2023.115772_bib217","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1021\/acsptsci.0c00130","article-title":"Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are nonspecific promiscuous SARS-CoV-2 main protease inhibitors","volume":"3","author":"Ma","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.ejmech.2023.115772_bib218","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104924","article-title":"Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry","volume":"182","author":"Gurard-Levin","year":"2020","journal-title":"Antivir. Res."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115772_bib219","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1021\/acs.jmedchem.1c00566","article-title":"Discovery and mechanism of SARS-CoV-2 main protease inhibitors","volume":"65","author":"Huff","year":"2021","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib220","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1038\/s41467-021-23313-7","article-title":"Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives","volume":"12","author":"Amporndanai","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115772_bib221","series-title":"Ebselen Derivatives Are Very Potent Dual Inhibitors of SARS-CoV-2 Proteases-PLpro and Mpro in in Vitro Studies","author":"Zmudzinski","year":"2020"},{"key":"10.1016\/j.ejmech.2023.115772_bib222","series-title":"Organoselenium Mild Electrophiles in the Inhibition of Mpro and SARSCoV-2 Replication","author":"Sancineto","year":"2020"},{"key":"10.1016\/j.ejmech.2023.115772_bib223","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104889","article-title":"Ebsulfur and Ebselen as highly potent scaffolds for the development of potential SARS-CoV-2 antivirals","volume":"112","author":"Sun","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2023.115772_bib224","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128526","article-title":"Discovery of highly potent SARS-CoV-2 Mpro inhibitors based on benzoisothiazolone scaffold","volume":"58","author":"Chen","year":"2022","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2023.115772_bib225","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105455","article-title":"The Mpro structure-based modifications of ebselen derivatives for improved antiviral activity against SARS-CoV-2 virus","volume":"117","author":"Qiao","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2023.115772_bib226","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104767","article-title":"Discovery of novel inhibitors against main protease (Mpro) of SARS-CoV-2 via virtual screening and biochemical evaluation","volume":"110","author":"Guo","year":"2021","journal-title":"Bioorg. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115772_bib227","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202100582","article-title":"Structure\u2010activity studies reveal scope for optimisation of ebselen\u2010type inhibition of SARS\u2010CoV\u20102 main protease","volume":"17","author":"Thun\u2010Hohenstein","year":"2022","journal-title":"ChemMedChem"},{"issue":"22","key":"10.1016\/j.ejmech.2023.115772_bib228","doi-asserted-by":"crossref","first-page":"6172","DOI":"10.1016\/j.bmcl.2013.08.112","article-title":"Discovery of N-(benzo [1, 2, 3] triazol-1-yl)-N-(benzyl) acetamido) phenyl) carboxamides as severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro inhibitors: identification of ML300 and noncovalent nanomolar inhibitors with an induced-fit binding","volume":"23","author":"Turlington","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"4","key":"10.1016\/j.ejmech.2023.115772_bib229","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1021\/acs.jmedchem.1c00598","article-title":"Structure-based optimization of ML300-derived, noncovalent inhibitors targeting the severe acute respiratory syndrome coronavirus 3CL protease (SARS-CoV-2 3CLpro)","volume":"65","author":"Han","year":"2021","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2023.115772_bib230","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41594-020-0440-6","article-title":"Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur","volume":"27","author":"Jin","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115772_bib231","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1021\/acscentsci.1c00039","article-title":"Potent noncovalent inhibitors of the main protease of SARS-CoV-2 from molecular sculpting of the drug perampanel guided by free energy perturbation calculations","volume":"7","author":"Zhang","year":"2021","journal-title":"ACS Cent. Sci."},{"issue":"8","key":"10.1016\/j.ejmech.2023.115772_bib232","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.str.2021.06.002","article-title":"Structure-guided design of a perampanel-derived pharmacophore targeting the SARS-CoV-2 main protease","volume":"29","author":"Deshmukh","year":"2021","journal-title":"Structure"},{"issue":"8","key":"10.1016\/j.ejmech.2023.115772_bib233","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1021\/acsmedchemlett.1c00326","article-title":"Optimization of triarylpyridinone inhibitors of the main protease of SARS-CoV-2 to low-nanomolar antiviral potency","volume":"12","author":"Zhang","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"issue":"12","key":"10.1016\/j.ejmech.2023.115772_bib234","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1021\/jm050852f","article-title":"Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies","volume":"49","author":"Tsai","year":"2006","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2023.115772_bib235","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1016\/j.bmcl.2010.04.118","article-title":"Synthesis, docking studies, and evaluation of pyrimidines as inhibitors of SARS-CoV 3CL protease","volume":"20","author":"Ramajayam","year":"2010","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib236","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1021\/acs.jcim.1c00851","article-title":"High-throughput virtual screening and validation of a SARS-CoV-2 main protease noncovalent inhibitor","volume":"62","author":"Clyde","year":"2021","journal-title":"J. Chem. Inf. Model."},{"issue":"23","key":"10.1016\/j.ejmech.2023.115772_bib237","doi-asserted-by":"crossref","first-page":"17366","DOI":"10.1021\/acs.jmedchem.1c01475","article-title":"Structural, electronic, and electrostatic determinants for inhibitor binding to subsites S1 and S2 in SARS-CoV-2 main protease","volume":"64","author":"Kneller","year":"2021","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115772_bib238","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.slasd.2022.01.001","article-title":"Discovery of SARS-CoV-2 main protease covalent inhibitors from a DNA-encoded library selection","volume":"27","author":"Ge","year":"2022","journal-title":"Slas Discovery"},{"key":"10.1016\/j.ejmech.2023.115772_bib239","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.2c00954","article-title":"Structure-based design of a dual-targeted covalent inhibitor against papain-like and main proteases of SARS-CoV-2","author":"Yu","year":"2022","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib240","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/14756366.2020.1850710","article-title":"Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors","volume":"36","author":"Chiou","year":"2021","journal-title":"J. Enzym. Inhib. Med. Chem."},{"issue":"22","key":"10.1016\/j.ejmech.2023.115772_bib241","doi-asserted-by":"crossref","first-page":"6832","DOI":"10.1021\/jm0501782","article-title":"A new lead for nonpeptidic active-site-directed inhibitors of the severe acute respiratory syndrome coronavirus main protease discovered by a combination of screening and docking methods","volume":"48","author":"Kaeppler","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115772_bib242","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114130","article-title":"In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease","volume":"231","author":"Xiong","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115772_bib243","series-title":"Discovery of Potent Pyrazoline-Based Covalent SARS-CoV-2 Main Protease Inhibitors","author":"Moon","year":"2022"},{"issue":"26","key":"10.1016\/j.ejmech.2023.115772_bib244","doi-asserted-by":"crossref","first-page":"5072","DOI":"10.1021\/jm960603e","article-title":"Design, synthesis, and evaluation of nonpeptidic inhibitors of human rhinovirus 3C protease","volume":"39","author":"Webber","year":"1996","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2023.115772_bib245","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1016\/j.bmcl.2005.04.027","article-title":"Synthesis and evaluation of isatin derivatives as effective SARS coronavirus 3CL protease inhibitors","volume":"15","author":"Chen","year":"2005","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"12","key":"10.1016\/j.ejmech.2023.115772_bib246","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1021\/jm0602357","article-title":"Isatin compounds as noncovalent SARS coronavirus 3C-like protease inhibitors","volume":"49","author":"Zhou","year":"2006","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib247","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.bmc.2013.11.028","article-title":"Synthesis, modification and docking studies of 5-sulfonyl isatin derivatives as SARS-CoV 3C-like protease inhibitors","volume":"22","author":"Liu","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115772_bib248","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112702","article-title":"Potent inhibitors of SARS-CoV-2 3C-like protease derived from N-substituted isatin compounds","volume":"206","author":"Liu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"1\u20133","key":"10.1016\/j.ejmech.2023.115772_bib249","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.febslet.2004.08.015","article-title":"Evaluation of metal-conjugated compounds as inhibitors of 3CL protease of SARS-CoV","volume":"574","author":"Hsu","year":"2004","journal-title":"FEBS Lett."},{"issue":"28","key":"10.1016\/j.ejmech.2023.115772_bib250","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1016\/j.febslet.2007.10.048","article-title":"Structural basis of mercury-and zinc-conjugated complexes as SARS-CoV 3C-like protease inhibitors","volume":"581","author":"Lee","year":"2007","journal-title":"FEBS Lett."},{"issue":"10","key":"10.1016\/j.ejmech.2023.115772_bib251","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0240079","article-title":"Biochemical screening for SARS-CoV-2 main protease inhibitors","volume":"15","author":"Coelho","year":"2020","journal-title":"PLoS One"},{"issue":"19","key":"10.1016\/j.ejmech.2023.115772_bib252","doi-asserted-by":"crossref","first-page":"10716","DOI":"10.1002\/anie.202016768","article-title":"ReI tricarbonyl complexes as coordinate covalent inhibitors for the SARS\u2010CoV\u20102 main cysteine protease","volume":"60","author":"Karges","year":"2021","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2023.115772_bib253","series-title":"Molecules Inhibit the Enzyme Activity of 3-chymotrypsin-like Cysteine Protease of SARS-CoV-2 Virus: the Experimental and Theory Studies","author":"He","year":"2020"},{"issue":"35","key":"10.1016\/j.ejmech.2023.115772_bib254","doi-asserted-by":"crossref","first-page":"12226","DOI":"10.1039\/D1DT02499J","article-title":"Zinc thiotropolone combinations as inhibitors of the SARS-CoV-2 main protease","volume":"50","author":"DeLaney","year":"2021","journal-title":"Dalton Trans."},{"issue":"8","key":"10.1016\/j.ejmech.2023.115772_bib255","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1039\/D1SC04515F","article-title":"Orally administered bismuth drug together with N-acetyl cysteine as a broad-spectrum anti-coronavirus cocktail therapy","volume":"13","author":"Wang","year":"2022","journal-title":"Chem. Sci."},{"issue":"9","key":"10.1016\/j.ejmech.2023.115772_bib256","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","article-title":"Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19","volume":"65","author":"Unoh","year":"2022","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2023.115772_bib257","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00697-22","article-title":"A randomized phase 2\/3 study of ensitrelvir, a novel oral SARS-CoV-2 3C-like protease inhibitor, in Japanese patients with mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection: results of the phase 2a part","volume":"66","author":"Mukae","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"issue":"19","key":"10.1016\/j.ejmech.2023.115772_bib258","doi-asserted-by":"crossref","first-page":"13343","DOI":"10.1021\/acs.jmedchem.2c01146","article-title":"Discovery and crystallographic studies of trisubstituted piperazine derivatives as non-covalent SARS-CoV-2 main protease inhibitors with high target specificity and low toxicity","volume":"65","author":"Gao","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115772_bib259","article-title":"Discovery and crystallographic studies of nonpeptidic piperazine derivatives as covalent SARS-CoV-2 main protease inhibitors","author":"Gao","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115772_bib260","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113789","article-title":"Discovery of juglone and its derivatives as potent SARS-CoV-2 main proteinase inhibitors","volume":"225","author":"Cui","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"36","key":"10.1016\/j.ejmech.2023.115772_bib261","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2111172118","article-title":"DNA-encoded chemistry technology yields expedient access to SARS-CoV-2 Mpro inhibitors","volume":"118","author":"Chamakuri","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2023.115772_bib262","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.bbrc.2021.03.096","article-title":"ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model","volume":"555","author":"Vandyck","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"8","key":"10.1016\/j.ejmech.2023.115772_bib263","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1021\/acs.jcim.1c00355","article-title":"Structure-based discovery of novel nonpeptide inhibitors targeting SARS-CoV-2 Mpro","volume":"61","author":"Yang","year":"2021","journal-title":"J. Chem. Inf. Model."},{"issue":"6557","key":"10.1016\/j.ejmech.2023.115772_bib264","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1126\/science.abg5827","article-title":"Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2","volume":"373","author":"Drayman","year":"2021","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.ejmech.2023.115772_bib265","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.apsb.2020.04.008","article-title":"Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19","volume":"10","author":"Liu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"issue":"23","key":"10.1016\/j.ejmech.2023.115772_bib266","doi-asserted-by":"crossref","first-page":"17530","DOI":"10.1021\/acs.jmedchem.1c01547","article-title":"Colloidal aggregators in biochemical SARS-CoV-2 repurposing screens","volume":"64","author":"O'Donnell","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115772_bib267","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2021.105075","article-title":"Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CLpro","volume":"190","author":"Du","year":"2021","journal-title":"Antivir. Res."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib268","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1021\/ci049809b","article-title":"Virtual screening of novel noncovalent inhibitors for SARS-CoV 3C-like proteinase","volume":"45","author":"Liu","year":"2005","journal-title":"J. Chem. Inf. Model."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib269","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3390\/pharmaceutics14010176","article-title":"Drug repurposing for the identification of compounds with anti-SARS-CoV-2 Capability via multiple targets","volume":"14","author":"Yu","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib270","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.bbrc.2005.05.095","article-title":"Screening of drugs by FRET analysis identifies inhibitors of SARS-CoV 3CL protease","volume":"333","author":"Liu","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib271","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s42003-020-01577-x","article-title":"Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents","volume":"4","author":"Mody","year":"2021","journal-title":"Commun. Biol."},{"issue":"7","key":"10.1016\/j.ejmech.2023.115772_bib272","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.scib.2020.10.018","article-title":"Crystal structure of SARS-CoV-2 main protease in complex with the natural product inhibitor shikonin illuminates a unique binding mode","volume":"66","author":"Li","year":"2021","journal-title":"Sci. Bull."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib273","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.bmc.2013.11.041","article-title":"Identification of novel drug scaffolds for inhibition of SARS-CoV 3-Chymotrypsin-like protease using virtual and high-throughput screenings","volume":"22","author":"Lee","year":"2014","journal-title":"Bioorg. Med. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2023.115772_bib274","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1016\/j.bmcl.2011.03.034","article-title":"Virtual screening identification of novel severe acute respiratory syndrome 3C-like protease inhibitors and in vitro confirmation","volume":"21","author":"Nguyen","year":"2011","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"10","key":"10.1016\/j.ejmech.2023.115772_bib275","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1248\/cpb.56.1400","article-title":"Design and synthesis of cinanserin analogs as severe acute respiratory syndrome coronavirus 3CL protease inhibitors","volume":"56","author":"Yang","year":"2008","journal-title":"Chem. Pharm. Bull."},{"issue":"17","key":"10.1016\/j.ejmech.2023.115772_bib276","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1021\/bi0361766","article-title":"Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro","volume":"43","author":"Bacha","year":"2004","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2023.115772_bib277","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ejmech.2019.02.002","article-title":"Chemical synthesis, crystal structure, versatile evaluation of their biological activities and molecular simulations of novel pyrithiobac derivatives","volume":"167","author":"Wu","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"17","key":"10.1016\/j.ejmech.2023.115772_bib278","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1021\/jm060207o","article-title":"Structure-based drug design and structural biology study of novel nonpeptide inhibitors of severe acute respiratory syndrome coronavirus main protease","volume":"49","author":"Lu","year":"2006","journal-title":"J. Med. Chem."},{"issue":"17","key":"10.1016\/j.ejmech.2023.115772_bib279","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1002\/anie.200704594","article-title":"Sensitized detection of inhibitory fragments and iterative development of non\u2010peptidic protease inhibitors by dynamic ligation screening","volume":"47","author":"Schmidt","year":"2008","journal-title":"Angew. Chem. Int. Ed."},{"issue":"24","key":"10.1016\/j.ejmech.2023.115772_bib280","doi-asserted-by":"crossref","first-page":"6553","DOI":"10.1021\/acs.jcim.2c00693","article-title":"Structure-based identification of naphthoquinones and derivatives as novel inhibitors of main protease Mpro and papain-like protease PLpro of SARS-CoV-2","volume":"62","author":"Santos","year":"2022","journal-title":"J. Chem. Inf. Model."},{"issue":"13","key":"10.1016\/j.ejmech.2023.115772_bib281","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1021\/jm050184y","article-title":"Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease","volume":"48","author":"Shie","year":"2005","journal-title":"J. Med. Chem."},{"issue":"19","key":"10.1016\/j.ejmech.2023.115772_bib282","doi-asserted-by":"crossref","first-page":"5928","DOI":"10.1016\/j.bmc.2012.07.038","article-title":"Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases","volume":"20","author":"Park","year":"2012","journal-title":"Bioorg. Med. Chem."},{"issue":"13","key":"10.1016\/j.ejmech.2023.115772_bib283","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1016\/j.bmc.2013.04.026","article-title":"Dieckol, a SARS-CoV 3CLpro inhibitor, isolated from the edible brown algae Ecklonia cava","volume":"21","author":"Park","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115772_bib284","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114030","article-title":"Discovery of 9, 10-dihydrophenanthrene derivatives as SARS-CoV-2 3CLpro inhibitors for treating COVID-19","volume":"228","author":"Zhang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib285","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01253-21","article-title":"Structure-based discovery and structural basis of a novel broad-spectrum natural product against the main protease of coronavirus","volume":"96","author":"Zhang","year":"2022","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115772_bib286","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3390\/md20030163","article-title":"Neoechinulin A as a promising SARS-CoV-2 Mpro inhibitor: in vitro and in silico study showing the ability of simulations in discerning active from inactive enzyme inhibitors","volume":"20","author":"Alhadrami","year":"2022","journal-title":"Mar. Drugs"},{"issue":"9","key":"10.1016\/j.ejmech.2023.115772_bib287","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3390\/biom11091366","article-title":"Bioguided isolation of cyclopenin analogues as potential SARS-CoV-2 Mpro inhibitors from Penicillium citrinum TDPEF34","volume":"11","author":"Thissera","year":"2021","journal-title":"Biomolecules"},{"issue":"5","key":"10.1016\/j.ejmech.2023.115772_bib288","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3390\/antibiotics10050542","article-title":"Cnicin as an anti-SARS-CoV-2: an integrated in silico and in vitro approach for the rapid identification of potential COVID-19 therapeutics","volume":"10","author":"Alhadrami","year":"2021","journal-title":"Antibiotics"},{"key":"10.1016\/j.ejmech.2023.115772_bib289","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104862","article-title":"Novel inhibitors of the main protease enzyme of SARS-CoV-2 identified via molecular dynamics simulation-guided in vitro assay","volume":"111","author":"Loschwitz","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2023.115772_bib290","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ijbiomac.2021.04.129","article-title":"Identification of Vitamin K3 and its analogues as covalent inhibitors of SARS-CoV-2 3CLpro","volume":"183","author":"Wang","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"issue":"22","key":"10.1016\/j.ejmech.2023.115772_bib291","doi-asserted-by":"crossref","first-page":"7849","DOI":"10.1016\/j.bmc.2010.09.050","article-title":"Synthesis and evaluation of pyrazolone compounds as SARS-coronavirus 3C-like protease inhibitors","volume":"18","author":"Ramajayam","year":"2010","journal-title":"Bioorg. Med. Chem."},{"issue":"13","key":"10.1016\/j.ejmech.2023.115772_bib292","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1016\/j.bmc.2016.05.013","article-title":"Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors","volume":"24","author":"Kumar","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115772_bib293","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ejmech.2017.05.045","article-title":"Discovery of unsymmetrical aromatic disulfides as novel inhibitors of SARS-CoV main protease: chemical synthesis, biological evaluation, molecular docking and 3D-QSAR study","volume":"137","author":"Wang","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2023.115772_bib294","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3923\/ijp.2015.749.756","article-title":"SARS-CoV 3C-like protease inhibitors of some newly synthesized substituted pyrazoles and substituted pyrimidines based on 1-(3-aminophenyl)-3-(1Hindol-3-yl) prop-2-en-1-one","volume":"11","author":"Mohamed","year":"2015","journal-title":"Int. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115772_bib295","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.bmcl.2005.11.018","article-title":"From genome to drug lead: identification of a small-molecule inhibitor of the SARS virus","volume":"16","author":"Dooley","year":"2006","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib296","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/1087057106296688","article-title":"Development and validation of a high-throughput screen for inhibitors of SARS CoV and its application in screening of a 100,000-compound library","volume":"12","author":"Severson","year":"2007","journal-title":"J. Biomol. Screen"},{"issue":"9","key":"10.1016\/j.ejmech.2023.115772_bib297","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.chembiol.2004.07.013","article-title":"Identification of novel small-molecule inhibitors of severe acute respiratory syndrome-associated coronavirus by chemical genetics","volume":"11","author":"Kao","year":"2004","journal-title":"Chem. Biol."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115772_bib298","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.febslet.2004.09.026","article-title":"Characterization of SARS-CoV main protease and identification of biologically active small molecule inhibitors using a continuous fluorescence-based assay","volume":"576","author":"Kao","year":"2004","journal-title":"FEBS Lett."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib299","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1039\/D0MD00282H","article-title":"Identification of LASSBio-1945 as an inhibitor of SARS-CoV-2 main protease (M PRO) through in silico screening supported by molecular docking and a fragment-based pharmacophore model","volume":"12","author":"Franco","year":"2021","journal-title":"RSC Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2023.115772_bib300","doi-asserted-by":"crossref","first-page":"7682","DOI":"10.1021\/acs.jmedchem.1c02214","article-title":"Penicillin derivatives inhibit the SARS-CoV-2 main protease by reaction with its nucleophilic cysteine","volume":"65","author":"Malla","year":"2022","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2023.115772_bib301","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1039\/D0CC06870E","article-title":"Mass spectrometry reveals potential of \u03b2-lactams as SARS-CoV-2 M pro inhibitors","volume":"57","author":"Malla","year":"2021","journal-title":"Chem. Commun."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib302","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1021\/acsmedchemlett.1c00299","article-title":"Design and evaluation of bispidine-based SARS-CoV-2 main protease inhibitors","volume":"13","author":"Shcherbakov","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115772_bib303","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114585","article-title":"Discovery of potent benzoxaborole inhibitors against SARS-CoV-2 main and dengue virus proteases","volume":"240","author":"K\u00fchl","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115772_bib304","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114803","article-title":"Discovery of novel SARS-CoV-2 3CL protease covalent inhibitors using deep learning-based screen","volume":"244","author":"Wang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115772_bib305","series-title":"Identification of Atovaquone and Mebendazole as Repurposed Drugs with Antiviral Activity against SARS-CoV-2 (Version 5)","author":"Ahmed","year":"2021"},{"issue":"11","key":"10.1016\/j.ejmech.2023.115772_bib306","doi-asserted-by":"crossref","first-page":"7095","DOI":"10.1128\/JVI.79.11.7095-7103.2005","article-title":"Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro","volume":"79","author":"Chen","year":"2005","journal-title":"J. Virol."},{"issue":"30","key":"10.1016\/j.ejmech.2023.115772_bib307","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2024302118","article-title":"Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay","volume":"118","author":"Jang","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2023.115772_bib308","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104786","article-title":"Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro","volume":"178","author":"Choy","year":"2020","journal-title":"Antivir. Res."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115772_bib309","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01114-20","article-title":"Antiviral efficacies of FDA-approved drugs against SARS-CoV-2 infection in ferrets","volume":"11","author":"Park","year":"2020","journal-title":"mBio"},{"issue":"3","key":"10.1016\/j.ejmech.2023.115772_bib310","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax"},{"key":"10.1016\/j.ejmech.2023.115772_bib311","doi-asserted-by":"crossref","DOI":"10.1016\/j.crchbi.2022.100025","article-title":"Repurposing Halicin as a potent covalent inhibitor for the SARS-CoV-2 main protease","volume":"2","author":"Yang","year":"2022","journal-title":"Current Research in Chemical Biology"},{"key":"10.1016\/j.ejmech.2023.115772_bib312","first-page":"1","article-title":"Identification of SARS-CoV-2 main protease inhibitors from FDA-approved drugs by artificial intelligence-supported activity prediction system","author":"Komatsu","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"5","key":"10.1016\/j.ejmech.2023.115772_bib313","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3390\/v13050873","article-title":"The repurposed drugs suramin and quinacrine cooperatively inhibit SARS-CoV-2 3CLpro in vitro","volume":"13","author":"Eberle","year":"2021","journal-title":"Viruses"},{"issue":"3","key":"10.1016\/j.ejmech.2023.115772_bib314","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1021\/acsptsci.0c00216","article-title":"Identification of inhibitors of SARS-CoV-2 3CL-pro enzymatic activity using a small molecule in vitro repurposing screen","volume":"4","author":"Kuzikov","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"9","key":"10.1016\/j.ejmech.2023.115772_bib315","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1021\/acs.jcim.1c00684","article-title":"Discovery of novel small-molecule inhibitors of SARS-CoV-2 main protease as potential leads for COVID-19 treatment","volume":"61","author":"Manandhar","year":"2021","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2023.115772_bib316","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13578-021-00564-x","article-title":"Ginkgolic acid and anacardic acid are specific covalent inhibitors of SARS-CoV-2 cysteine proteases","volume":"11","author":"Chen","year":"2021","journal-title":"Cell Biosci."},{"key":"10.1016\/j.ejmech.2023.115772_bib317","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128099","article-title":"Promising anti-SARS-CoV-2 drugs by effective dual targeting against the viral and host proteases","volume":"43","author":"Elseginy","year":"2021","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"16","key":"10.1016\/j.ejmech.2023.115772_bib318","doi-asserted-by":"crossref","first-page":"9057","DOI":"10.3390\/ijms22169057","article-title":"Iterated virtual screening-assisted antiviral and enzyme inhibition assays reveal the discovery of novel promising anti-SARS-CoV-2 with dual activity","volume":"22","author":"Hamdy","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"15","key":"10.1016\/j.ejmech.2023.115772_bib319","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115772_bib320","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciac443","article-title":"Effectiveness of Paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients","volume":"76","author":"Najjar-Debbiny","year":"2023","journal-title":"Clin. Infect. Dis."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115772_bib321","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.00869-22","article-title":"Genetic surveillance of SARS-CoV-2 Mpro reveals high sequence and structural conservation prior to the introduction of protease inhibitor Paxlovid","volume":"13","author":"Lee","year":"2022","journal-title":"mBio"},{"issue":"51","key":"10.1016\/j.ejmech.2023.115772_bib322","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.add7197","article-title":"Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system","volume":"8","author":"Zhou","year":"2022","journal-title":"Sci. Adv."},{"issue":"10","key":"10.1016\/j.ejmech.2023.115772_bib323","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s00044-022-02951-6","article-title":"The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations","volume":"31","author":"Joyce","year":"2022","journal-title":"Med. Chem. Res."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib324","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy","volume":"13","author":"Li","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115772_bib325","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1038\/s41467-019-11429-w","article-title":"Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations","volume":"10","author":"de Wispelaere","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115772_bib326","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113814","article-title":"Indomethacin-based PROTACs as pan-coronavirus antiviral agents","volume":"226","author":"Desantis","year":"2021","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423007390?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423007390?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:00:13Z","timestamp":1759330813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423007390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":326,"alternative-id":["S0223523423007390"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115772","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115772","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115772"}}